Printer Friendly

Spinal Restoration Reaches Agreement with FDA on the Special Protocol Assessment (SPA) for the Phase 3 Trial of the Biostat[R] System.

Phase 3 Study Enrollment to Begin in Early 2010

AUSTIN, Texas -- Spinal Restoration, Inc. announced today it has received a Special Protocol Assessment concurrence letter from the U.S. Food and Drug Administration (FDA) for the design of its Phase 3 study of the Biostat System for the treatment of chronic discogenic low back pain. The SPA is an agreement between Spinal Restoration and the FDA that the Phase 3 study design, endpoints, and planned statistical analysis are adequate to provide necessary data that, depending on outcome, could support a Biologic License Application (BLA). Spinal Restoration anticipates patient enrollment in this Phase 3 study will begin in early 2010.

The Phase 3 trial is a multicenter, randomized, blinded (patient and evaluator), placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain. Study success will be determined by comparing the success rates between the investigational and control populations at the 6-month primary endpoint.

"SPA concurrence is a momentous achievement in the regulatory pathway for the Biostat System," said Gary Sabins, President and CEO. "Spinal Restoration is now well positioned to be the first company to initiate a Phase 3 clinical study of a biologic intradiscal therapy for the treatment of chronic low back pain."

The Biostat System consists of BIOSTAT BIOLOGX([R])Fibrin Sealant, a human derived, resorbable biologic tissue sealant, and a proprietary application system designed to safely deliver the biologic to the intervertebral disc. Application of BIOSTAT BIOLOGX Fibrin Sealant to the disc may alleviate discogenic pain by sealing the painful disc disruptions, reducing inflammation, and enhancing tissue repair.

About Spinal Restoration

Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain. Visit www.spinalrestoration.com for more information.
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 15, 2009
Words:348
Previous Article:OpenSpan and Call Center School to Host Webinar on Reducing Training Time While Improving Efficiency.
Next Article:Slogan Contest to Foster Business Optimism for 2010 Announced.


Related Articles
Spinal Restoration, Baxter form partnership.
Alseres Receives Special Protocol Assessment Agreement from FDA for Phase III Trial of Altropane.
D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke...
D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke...
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011...
terna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the...
Soligenix initiates confirmatory Phase 3 clinical trial of orBec in Acute GI HvHD.
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in the Treatment of...
Keryx, FDA announce Special Protocol Agreement on design of a Phase 3 clinical program for kidney drug Zerenex.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters